Tirzepatide in Australia: What It Is, How It Works, and How to Get a Prescription in 2026
TL;DR
Tirzepatide is a dual action GLP1 and GIP receptor agonist approved by the TGA in Australia for type 2 diabetes and chronic weight management. It is sold under the brand name Mounjaro and is available by prescription only. Tirzepatide is not listed on the PBS for either indication as of August 2026, so patients pay the full private cost. An AHPRA registered GP can assess your eligibility and prescribe during a telehealth consultation.
Introduction
Tirzepatide in Australia has become one of the most searched weight loss medications in the country, with over 6,600 Australians looking for information about it every month. That level of interest is not surprising. The SURMOUNT 1 clinical trial, published in The New England Journal of Medicine, showed that participants taking tirzepatide at the highest dose lost an average of 22.5% of their body weight over 72 weeks. No other single agent weight loss medication has matched that result in a published Phase 3 trial.
Yet despite the strong clinical evidence, access in Australia remains confusing. Tirzepatide is TGA approved but not PBS subsidized. Compounded versions were banned in October 2024. Pharmacy pricing varies widely. And many Australians still do not know whether their GP can prescribe it or whether they need a specialist referral.
This guide explains what tirzepatide is, how it works at a molecular level, what it costs in Australia right now, and exactly how to get a prescription through a telehealth consultation with an AHPRA registered doctor.
What Is Tirzepatide and How Does It Differ from Other GLP1 Medications?
Tirzepatide is a once-weekly injectable prescription medication that activates two hormone receptors simultaneously: GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). This dual receptor mechanism is what distinguishes tirzepatide from single-target GLP-1 medications like semaglutide (the active ingredient in Ozempic and Wegovy).
GLP1 receptor activation slows gastric emptying, reduces appetite, and stimulates insulin release after meals. GIP receptor activation adds a second pathway that enhances the body’s ability to process glucose and may independently influence fat metabolism. By acting on both receptors simultaneously, tirzepatide produces greater reductions in body weight and blood sugar than GLP1 only medications.
The SURMOUNT 5 head to head trial, published in The New England Journal of Medicine in 2026, confirmed this directly. Participants taking tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared to 13.7% for those taking semaglutide. Both groups received the maximum tolerated dose of each medication.
Tirzepatide was developed by Eli Lilly and is sold under the brand name Mounjaro in Australia. It received TGA registration for type 2 diabetes in mid 2023 and subsequently received TGA approval for chronic weight management.
Is Tirzepatide TGA Approved and PBS Listed in Australia?
Tirzepatide is TGA approved in Australia for two indications: the treatment of type 2 diabetes mellitus and chronic weight management in adults with a BMI of 30 or higher (or 27 or higher with at least one weight related comorbidity such as hypertension, dyslipidaemia, or obstructive sleep apnoea).
However, tirzepatide is not listed on the Pharmaceutical Benefits Scheme for either indication as of August 2026. Eli Lilly Australia made four separate submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) for a type 2 diabetes PBS listing, and all four were unsuccessful. The most recent rejection was confirmed in April 2026.
For weight management, the PBAC recommended PBS listing for semaglutide (Wegovy) in January 2026, and price negotiations between Novo Nordisk and the government are ongoing. No equivalent PBS recommendation has been issued for tirzepatide in the weight management indication.
What this means in practice: every Australian who uses tirzepatide pays the full private prescription price. There is no government subsidy, and Medicare does not rebate the cost of the medication or the pharmacy dispensing fee.
How Much Does Tirzepatide Cost in Australia?
Without PBS subsidy, the monthly out of pocket cost of tirzepatide in Australia varies depending on the dose, pharmacy, and format (pre filled pen vs single use vial). As a general guide, patients can expect to pay approximately $300 to $600 per month at retail pharmacy pricing, though costs increase at higher doses.
Pricing varies significantly between pharmacies. Major chains like Chemist Warehouse, Priceline Pharmacy, and Terry White Chemmart each set their own retail markup on the wholesale cost. It is worth calling several pharmacies in your area to compare pricing before filling your prescription.
Some patients explore compounded tirzepatide as a lower cost alternative. However, the TGA banned compounded versions of GLP1 receptor agonists (including tirzepatide and semaglutide) from October 2024, citing safety and quality concerns. Any compounded tirzepatide product available after that date operates outside TGA regulations, and prescribers and patients should be aware of the legal and clinical risks.
A telehealth consultation to assess your eligibility and obtain a prescription is a separate cost from the medication itself. At Holistica Health, an initial weight loss consultation costs $99.
What Does the Clinical Evidence Show About Tirzepatide for Weight Loss?
The SURMOUNT clinical trial program is the largest body of Phase 3 evidence supporting tirzepatide for chronic weight management. The program enrolled over 5,000 participants across six global trials.
Key findings from the SURMOUNT trials:
SURMOUNT 1 (NEJM, 2022): Participants without type 2 diabetes lost an average of 16.0% (5 mg dose), 21.4% (10 mg dose), and 22.5% (15 mg dose) of their body weight over 72 weeks. At the two higher doses, 96% of participants achieved at least 5% weight loss, and over 50% achieved 20% or more weight loss.
SURMOUNT 3 (Nature Medicine, 2024): Participants who had already lost at least 5% body weight through intensive lifestyle intervention lost an additional 18.4% with tirzepatide over 72 weeks, compared to a 2.5% regain with placebo.
SURMOUNT 4 (JAMA, 2024): Participants who continued tirzepatide for a further 52 weeks after an initial 36 week treatment period maintained their weight loss, while those switched to placebo regained an average of 14% body weight. This trial demonstrated that ongoing treatment is necessary to sustain the benefits.
SURMOUNT 5 (NEJM, 2026): The first direct comparison between tirzepatide and semaglutide showed tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide over 72 weeks.
A 2026 real world observational study of 4,309 Australian patients using tirzepatide through a digital weight loss service confirmed that engaged users achieved meaningful weight loss, though adherence was a key factor in outcomes (published in Diabetes, Obesity and Metabolism).
What Are the Common Side Effects of Tirzepatide?
Tirzepatide shares a similar side effect profile with other GLP1 class medications. The most frequently reported side effects in clinical trials were gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, and constipation. These effects are most common during the dose escalation phase and tend to reduce in frequency and severity as the body adjusts.
The standard prescribing protocol starts tirzepatide at a 2.5 mg weekly dose and increases gradually in 2.5 mg increments (to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg) based on tolerability and clinical response. This slow titration schedule is specifically designed to minimize gastrointestinal side effects.
Serious adverse events reported in clinical trials included pancreatitis, gallbladder events (cholelithiasis), and injection site reactions, though these occurred at low rates. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
A prescribing doctor will assess your full medical history, current medications, and contraindications before determining whether tirzepatide is appropriate for you.
How Do You Get a Tirzepatide Prescription in Australia?
Any AHPRA registered medical practitioner in Australia can prescribe tirzepatide. You do not need a specialist referral or a hospital based assessment. A general practitioner with appropriate clinical knowledge can assess your eligibility and issue a prescription during a standard or telehealth consultation.
The typical process involves three steps. First, you complete a medical screening questionnaire covering your weight history, BMI, existing conditions, and current medications. Second, you attend a consultation (in person or via telehealth) where the doctor reviews your screening information, discusses treatment options, and determines whether tirzepatide is clinically appropriate for you. Third, if eligible, the doctor writes a private prescription that you can fill at any Australian pharmacy.
Telehealth makes this process accessible from anywhere in Australia. At Holistica Health, patients complete a pre screening eligibility checklist online, then book a video consultation with an AHPRA registered GP. The clinic operates seven days a week (9:00 AM to 7:00 PM AWST) and serves patients in every Australian state and territory.
Once you have your prescription, you can fill it at any retail pharmacy. The medication is stored between 2 and 8 degrees Celsius and is administered as a subcutaneous injection once per week. Your pharmacist can demonstrate the correct injection technique.
Tirzepatide vs Semaglutide: Which One Should You Choose?
Both tirzepatide and semaglutide are TGA approved, evidence based medications for weight management in Australia. The choice between them depends on your clinical profile, cost considerations, and response to treatment.
Tirzepatide (Mounjaro) acts on two receptors (GLP1 + GIP) and has produced greater average weight loss in head to head trials. Semaglutide (Ozempic for diabetes, Wegovy for weight management) acts on GLP1 only and has the longer track record in Australian clinical practice, including PBS subsidy for type 2 diabetes under the Ozempic brand.
Key differences to discuss with your doctor:
Weight loss magnitude: Tirzepatide produced 20.2% average weight loss vs 13.7% for semaglutide in the SURMOUNT 5 trial.
Cost: Neither is PBS listed for weight management. Tirzepatide is generally more expensive at retail pricing.
Supply: Semaglutide experienced significant supply shortages in Australia through 2024 and 2025. As of February 2026, the TGA reports no current shortages of either medication.
Cardiovascular data: Semaglutide (SELECT trial) has published cardiovascular outcomes data. The tirzepatide cardiovascular outcomes trial (SURMOUNT MMO) data is still emerging.
Your prescribing doctor can help you weigh these factors against your individual health profile. The right medication is the one that is clinically appropriate, tolerable, and financially sustainable for your situation.
Frequently Asked Questions
Is tirzepatide the same as Mounjaro?
Yes. Tirzepatide is the active pharmaceutical ingredient, and Mounjaro is the brand name under which Eli Lilly markets it in Australia. They refer to the same medication. In clinical literature and TGA regulatory documents, the generic name tirzepatide is used. In pharmacy and patient contexts, the brand name Mounjaro is more commonly recognized.
Can I get tirzepatide on the PBS in Australia?
No. As of August 2026, tirzepatide (Mounjaro) is not listed on the PBS for type 2 diabetes or chronic weight management. Eli Lilly submitted four unsuccessful applications for a type 2 diabetes PBS listing, with the most recent rejection confirmed in April 2026. Patients pay the full private prescription cost at retail pharmacies.
Do I need a specialist referral to get tirzepatide?
No. Any AHPRA registered general practitioner in Australia can prescribe tirzepatide after a clinical assessment. You do not need a referral to an endocrinologist, bariatric physician, or any other specialist. Telehealth GPs can assess eligibility and issue a prescription during a video consultation.
Is compounded tirzepatide legal in Australia?
The TGA banned compounded versions of GLP1 receptor agonists, including tirzepatide and semaglutide, from October 2024. Any compounded tirzepatide product available in Australia after that date operates outside current TGA regulations. Patients should only use TGA registered tirzepatide (Mounjaro) obtained through a valid prescription from an AHPRA registered prescriber.
How long does it take for tirzepatide to start working?
Most patients begin to notice reduced appetite and early weight changes within the first four to six weeks of treatment. However, the dose escalation protocol starts at the lowest dose (2.5 mg) and increases gradually over several months. The full therapeutic effect is typically observed after reaching the target maintenance dose, which may take 16 to 20 weeks depending on tolerability. The SURMOUNT clinical trials measured primary outcomes at 72 weeks (approximately 17 months).
What to Do Next
Tirzepatide represents a significant advance in medical weight management, with the strongest weight loss evidence of any single agent medication currently available in Australia. It is TGA approved, supported by over 5,000 participants across six Phase 3 trials, and accessible through any AHPRA registered prescriber.
The key barrier remains cost. Without PBS subsidy, patients pay the full retail price, which makes an informed conversation with your doctor about expected outcomes, treatment duration, and financial sustainability an important first step.
If you are considering tirzepatide and want to find out whether you are eligible, complete the Holistica Health pre screening eligibility checklist to book a telehealth consultation with an AHPRA registered GP. The clinic serves patients across all Australian states and territories, seven days a week.